However, cannabidiol as an anxiety reducer has almost none of these issues. One study had participants who took either 600 mg of CBD or a placebo drug. In a speaking test that followed, the group which underwent CBD oil treatment showed less anxiety. They also had a smaller degree of cognitive impairment and felt less discomfort overall as they spoke. In other words, their results were better than those of the placebo group.
Generalized pain, for instance, has dozens upon dozens of high profile research and clinical studies that have been carried out in universities and laboratories around the globe. One of the most well-publicized of these studies took place back in 2008, in which results determined that “cannabinoid analgesics (pain relievers) have generally been well tolerated in clinical trials … with acceptable adverse event profiles (meaning acceptable effectiveness for practical use).
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from